Bolt Biotherapeutics Inc [NASDAQ: BOLT] price plunged by -0.62 percent to reach at $0.0.
The one-year BOLT stock forecast points to a potential upside of 64.0. The average equity rating for BOLT stock is currently 3.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Bolt Biotherapeutics Inc [BOLT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BOLT shares is $1.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BOLT stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Bolt Biotherapeutics Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on January 06, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Outperform. The new note on the price target was released on March 02, 2021, representing the official price target for Bolt Biotherapeutics Inc stock. Previously, the target price had yet another raise to $40, while Stifel analysts kept a Buy rating on BOLT stock.
The Average True Range (ATR) for Bolt Biotherapeutics Inc is set at 0.04, with the Price to Sales ratio for BOLT stock in the period of the last 12 months amounting to 2.45. The Price to Book ratio for the last quarter was 0.33, with the Price to Cash per share for the same quarter was set at 1.43.
BOLT Stock Performance Analysis:
Bolt Biotherapeutics Inc [BOLT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.82. With this latest performance, BOLT shares dropped by -6.55% in over the last four-week period, additionally sinking by -17.53% over the last 6 months – not to mention a drop of -32.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BOLT stock in for the last two-week period is set at 52.50, with the RSI for the last a single of trading hit 57.66, and the three-weeks RSI is set at 50.09 for Bolt Biotherapeutics Inc [BOLT]. The present Moving Average for the last 50 days of trading for this stock 0.6300, while it was recorded at 0.6003 for the last single week of trading, and 0.8499 for the last 200 days.
Insight into Bolt Biotherapeutics Inc Fundamentals:
Bolt Biotherapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.16 and a Current Ratio set at 3.16.
Bolt Biotherapeutics Inc [BOLT] Institutonal Ownership Details
There are presently around $58.19%, or 60.27%% of BOLT stock, in the hands of institutional investors. The top three institutional holders of BOLT stocks are: TANG CAPITAL MANAGEMENT LLC with ownership of 3.81 million shares, which is approximately 10.0156%. VIVO CAPITAL, LLC, holding 3.52 million shares of the stock with an approximate value of $$2.64 million in BOLT stocks shares; and VIVO CAPITAL, LLC, currently with $$2.07 million in BOLT stock with ownership which is approximately 7.2355%.
